671 related articles for article (PubMed ID: 21034228)
1. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
[TBL] [Abstract][Full Text] [Related]
4. Combination of initial stimulation thyroglobulins and staging system by revised ATA guidelines can elaborately discriminate prognosis of patients with differentiated thyroid carcinoma after high-dose remnant ablation.
Kim MH; Ko SH; Bae JS; Lim DJ; Baek KH; Lee JM; Kang MI; Cha BY
Clin Nucl Med; 2012 Nov; 37(11):1069-74. PubMed ID: 22996253
[TBL] [Abstract][Full Text] [Related]
5. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
[TBL] [Abstract][Full Text] [Related]
6. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
7. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
8. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
[TBL] [Abstract][Full Text] [Related]
9. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
[TBL] [Abstract][Full Text] [Related]
10. A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better.
Jeon MJ; Kim M; Park S; Oh HS; Kim TY; Kim WB; Shong YK; Kim WG
Thyroid; 2018 Feb; 28(2):187-192. PubMed ID: 29179642
[TBL] [Abstract][Full Text] [Related]
11. Dynamic prediction of the risk of recurrence in patients over 60 years of age with differentiated thyroid carcinoma.
Morosán YJ; Parisi C; Urrutia MA; Rosmarin M; Schnitman M; Serrano L; Luciani W; Faingold C; Pitoia F; Brenta G
Arch Endocrinol Metab; 2016 Aug; 60(4):348-54. PubMed ID: 26910621
[TBL] [Abstract][Full Text] [Related]
12. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
[TBL] [Abstract][Full Text] [Related]
13. The predictive value for excellent response to initial therapy in differentiated thyroid cancer: preablation-stimulated thyroglobulin better than the TNM stage.
Zhang Y; Hua W; Zhang X; Peng J; Liang J; Gao Z
Nucl Med Commun; 2018 May; 39(5):405-410. PubMed ID: 29557849
[TBL] [Abstract][Full Text] [Related]
14. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response.
Vaisman F; Tala H; Grewal R; Tuttle RM
Thyroid; 2011 Dec; 21(12):1317-22. PubMed ID: 22136267
[TBL] [Abstract][Full Text] [Related]
15. Neck Ultrasound in Patients with Follicular Thyroid Carcinoma.
Segkos K; Porter K; Senter L; Ringel MD; Nabhan FA
Horm Cancer; 2018 Dec; 9(6):433-439. PubMed ID: 30088223
[TBL] [Abstract][Full Text] [Related]
16. Pediatric Thyroid Cancer: Postoperative Classifications and Response to Initial Therapy as Prognostic Factors.
Lazar L; Lebenthal Y; Segal K; Steinmetz A; Strenov Y; Cohen M; Yaniv I; Yackobovitch-Gavan M; Phillip M
J Clin Endocrinol Metab; 2016 May; 101(5):1970-9. PubMed ID: 26930182
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy.
Vaisman F; Momesso D; Bulzico DA; Pessoa CH; Dias F; Corbo R; Vaisman M; Tuttle RM
Clin Endocrinol (Oxf); 2012 Jul; 77(1):132-8. PubMed ID: 22248037
[TBL] [Abstract][Full Text] [Related]
18. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.
Pitoia F; Jerkovich F; Urciuoli C; Schmidt A; Abelleira E; Bueno F; Cross G; Tuttle RM
Thyroid; 2015 Nov; 25(11):1235-42. PubMed ID: 26132983
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
20. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
[No Abstract] [Full Text] [Related]
[Next] [New Search]
